Dose Insider / Analyses / Switching from Wegovy to Zepbound

Switching From Wegovy to ZepboundThe Starting Dose, the Timing, and What the Evidence Covers

Updated November 20, 2026 · 23 min read · FDA labels, SURMOUNT-5

There is no official rule for switching from Wegovy to Zepbound. The Zepbound label has one starting dose for everyone, 2.5 mg a week for 4 weeks, and gives no separate schedule for people coming from another drug. The Wegovy label says semaglutide stays in the body for 5 to 7 weeks after the last injection, so for about a month both drugs are present.

62%of the usual Wegovy peak is still there on the first Zepbound day
Wegovy left after the last doseShare of its usual weekly peak, model from the label half-lifeDay 762%Day 1431%Day 2116%Day 288%Day 354%Wegovy left after the lastdoseShare of its usual weekly peak, model from thelabel half-lifeDay 762%Day 1431%Day 2116%Day 288%Day 354%

The four weeks on Zepbound 2.5 mg are the weeks in which the semaglutide drains away.

On this page

This page shows that overlap by date for your own switch. Then it goes through what the labels and regulators say, which doses of the two drugs produced similar results, whether people lose more after switching, what happens with side effects, what changes for people on the pill, and the reverse switch.

What does the switch look like by date?

Enter the date of your last Wegovy dose and choose when the first Zepbound dose follows. The chart shows the semaglutide fading and the tirzepatide building up through the label's first two steps.

Your switchLabel half-lives
First Zepbound dose, days after it
Wegovy left—
Wegovy gone by—
Semaglutide, from WegovyTirzepatide, from Zepbound

    Log both drugs in the app and it keeps one timeline across the switch.

    Open the app

    The numbers along the bottom are weeks after the last Wegovy dose. Each line is a share of that drug's own usual level: semaglutide against its weekly peak on a steady dose, tirzepatide against the settled peak on 5 mg. Zepbound steps follow the label: 2.5 mg for 4 weeks, then 5 mg. A model from the label half-lives, not a measurement.

    The calculator opens with no gap: the first Zepbound dose goes in a week after the last Wegovy dose, on the day the next Wegovy injection would have been due. On that day the semaglutide level is at about 62% of its usual weekly peak, which is its ordinary low point before a new dose. From there it only falls.

    Days after the last Wegovy doseSemaglutide left, share of its usual peakIf Zepbound started on day 7
    762%first 2.5 mg dose
    1431%second 2.5 mg dose
    2116%third 2.5 mg dose
    288%fourth 2.5 mg dose
    354%first 5 mg dose

    Our one-compartment model with the Wegovy label's half-life of about 1 week.

    The Wegovy label states the same thing in words. Semaglutide has "an elimination half-life of approximately 1 week" and "will be present in the circulation for about 5 to 7 weeks after the last injectable dose".2 A switch is therefore never a clean cut. For the first month on Zepbound, some of the previous drug is still in the blood.

    That has a useful side. The four weeks on Zepbound's 2.5 mg starter dose are exactly the weeks in which the semaglutide is draining away. The fading drug covers part of the stretch in which the new one is still at a dose the label does not count as a treatment dose. By the time Zepbound moves to 5 mg, in week 5, the semaglutide is down to a few percent.

    The first eight weeks, in levels

    The model gives both drugs week by week for a switch with no gap. The tirzepatide column is the weekly peak, as a share of the settled peak on 5 mg.

    Week on ZepboundDose mgTirzepatide peak, share of settled 5 mgSemaglutide left at the start of the week
    12.530%62%
    22.543%31%
    32.547%16%
    42.549%8%
    5580%4%
    6592%2%
    7597%1%
    8599%under 1%

    Our model with the label half-lives: about 5 days for tirzepatide, about 1 week for semaglutide.

    The two columns cross in the second week. By week 5 the handover is complete: the old drug is nearly gone and the new one is at four fifths of its settled 5 mg level. The weakest stretch is weeks 3 and 4, when the semaglutide has dropped under a fifth of its usual level and the tirzepatide is still at the starter dose.

    A worked example

    Take a last Wegovy dose on Monday, January 4. With no gap, the Zepbound 2.5 mg doses fall on January 11, 18 and 25 and February 1. The first 5 mg dose is on February 8. The semaglutide drops under 5% of its usual peak around February 6, about 33 days after the last Wegovy dose. The level on 5 mg has settled by March 8, which is also the earliest date the label would allow a move to 7.5 mg.

    Now take the same last dose with a four-week wait. The first Zepbound dose is on February 1, when the semaglutide is already down to 8%. The first 5 mg dose is on March 1, and the level settles by March 29. Three weeks later than in the first plan, with February spent on a starter dose and almost no semaglutide behind it.

    If there is a gap

    Choose 28 or 35 days and the picture changes. The semaglutide has mostly gone before the first Zepbound dose arrives, and then four more weeks pass on 2.5 mg. That is about two months with little active drug in the body. The trials of stopping these drugs show what tends to happen in such a stretch: weight starts to return. People who stopped Wegovy after 20 weeks regained 6.9% of their weight over the following 48 weeks, while those who continued lost a further 7.9%.8

    A gap is sometimes unavoidable, for supply or insurance reasons. The calculator shows what it costs in drug level, and the article on what happens after stopping has the regain figures.

    What do the labels and regulators say about switching?

    Very little, and what they say fits in four statements.

    The Zepbound label has one starting dose. "The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." After 4 weeks the dose goes to 5 mg, and it may then rise in steps of 2.5 mg after at least 4 weeks on each.1 The label makes no exception for people who have been on another drug of this kind.

    Neither label has a section on switching between the two drugs. The Wegovy label has a section on moving between its own injection and its own tablets, and nothing on moving to tirzepatide.2

    Both labels advise against taking the two together. The Zepbound label: "Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended." The Wegovy label says the same about using it with any other GLP-1 receptor agonist. A switch means stopping one and starting the other, not adding one to the other.

    The UK regulator asks for a professional to be involved. Its guidance for patients reads: "Before switching from one GLP-1 medicine to another, including between brands containing the same type of GLP-1, you should consult a healthcare professional for advice." It gives the reason: the medicines "vary in how strong they are", and "switching without medical advice may increase the risk of experiencing side effects or make the treatment less effective".3

    QuestionZepbound labelWegovy label
    Starting dose2.5 mg for 4 weeks, for everyone0.25 mg for 4 weeks, for everyone
    Section on switching to the other drugnonenone
    Using both togethernot recommendednot recommended
    Half-lifeabout 5 daysabout 1 week
    Time to the top dose at the fastest pace20 weeks, to 15 mg16 weeks, to 2.4 mg

    A group of specialists who reviewed the question in 2026 opens with the same finding: "Currently, there are no available guidelines for switching from semaglutide to tirzepatide".4 Everything beyond the label's 2.5 mg start is clinical judgement.

    Which Zepbound dose matches my Wegovy dose?

    There is no conversion table in either label. What exists is the average result at each dose in each drug's own trials, and one trial that compared the two drugs directly.

    Average loss by doseTrials
    Show

    Average loss as a percent of starting weight. Own trials: Wegovy 2.4 mg in its main trial, Wegovy 7.2 mg in its high-dose trial, Zepbound in its main trial. Results from different trials are not a direct comparison.

    Drug and doseAverage lossWhenTrial
    Wegovy 2.4 mg14.9%week 68its main trial
    Wegovy 2.4 mg15.5%week 72the high-dose trial
    Wegovy 7.2 mg18.8%week 72the high-dose trial
    Zepbound 5 mg15.0%week 72its main trial
    Zepbound 10 mg19.5%week 72its main trial
    Zepbound 15 mg20.9%week 72its main trial

    Wegovy and Zepbound labels, clinical studies sections.

    On these averages, Wegovy 2.4 mg and Zepbound 5 mg sit together at about 15%. Zepbound 10 mg and Wegovy's newer 7.2 mg dose sit together at about 19%. Zepbound 15 mg is a little above both. This is as close to a matching table as the published figures allow, and it comes with a warning: the trials enrolled different people and ran for different lengths, so the lines are rough.

    The specialists' 2026 review builds on comparisons of this kind. Its authors propose "approximate efficacy-matched switching dose bands" and argue that starting a switcher at a matched dose "is more practical than mandatory lowest-dose initiation, which naturally risks a 'therapeutic gap' and subsequent weight regain". They are clear about the status of that advice: it applies "until prospective switching trials validate exact conversions", with doses adjusted "every 4–8 weeks based on individual tolerability".4

    So there are two positions. The label says 2.5 mg for everyone. A published expert opinion says a higher starting dose may make sense for someone already used to a full dose of Wegovy, because four weeks on a starter dose is a step down in effect. Starting above 2.5 mg is outside the label, and it is a decision only a prescriber can take. What the calculator above adds is that the step down is softened by the semaglutide still in the body when there is no gap.

    Will I lose more weight after switching?

    On average, people lose more on Zepbound than on Wegovy. Whether a person who switches gains the whole difference has not been tested in a trial.

    The comparison comes from SURMOUNT-5, the one trial that assigned people to one drug or the other. It enrolled 751 adults with obesity and without diabetes. Half took tirzepatide and half took semaglutide, each at the highest dose they tolerated, for 72 weeks.5

    At week 72Tirzepatide, 10 or 15 mgSemaglutide, 1.7 or 2.4 mg
    Average weight change−20.2%−13.7%
    Average waist change−18.4 cm−13.0 cm

    Aronne and colleagues, New England Journal of Medicine 2025. The trial was open-label and funded by Eli Lilly.

    The gap was 6.5 percentage points of body weight and 5.4 cm of waist. For someone who started at 230 lb, that is the difference between losing about 46 lb and about 32 lb. The authors also report that people on tirzepatide were more likely to reach losses of 10%, 15%, 20% and 25%.

    Everyone in that trial was starting treatment for the first time. Nobody in it had been on Wegovy for a year and then changed. A person who switches after reaching a plateau on Wegovy starts from a different place: lighter than at the beginning, with appetite already adapted to one drug. It is reasonable to expect further loss after moving to a drug that produces larger average losses. How much is the open question, and the specialists' review says so when it asks for "prospective switching trials".4

    What the modelling and the diabetes studies add

    Three pieces of evidence look at switching itself, all in people with type 2 diabetes, where the same two substances are sold as Ozempic and Mounjaro.

    A model built from the diabetes trial programmes of both drugs simulated the switch. It predicted that people on semaglutide at 0.5 to 2 mg would have lost 3.6 to 6.9 kg by week 26, and that after switching to tirzepatide at 5 to 15 mg their loss would reach 6.5 to 12.1 kg by week 66. Its authors concluded that switching, "even at the lowest approved maintenance dose of 5 mg, showed the potential to further improve HbA1c and body weight reductions".6 This is a simulation, not a trial.

    A randomized trial tested a switch from a different drug of the family, dulaglutide. Adults whose diabetes was not well controlled on dulaglutide either had their dulaglutide dose raised or switched to tirzepatide. Switching "resulted in greater improvements in glycemic control and body weight", and in the subgroup analysis the advantage held in every group examined.9

    And a small clinic series from Japan followed 15 people who moved from semaglutide 1 mg to tirzepatide because their weight loss had been inadequate. All started tirzepatide at 2.5 mg. Over three months, the five who reached 10 mg lost 6.6 kg on average, a result that did not reach statistical significance in so small a group, and the ten who stayed at 7.5 mg showed no clear change.7

    EvidenceWhoWhat it showsHow strong
    SURMOUNT-5751 adults with obesity, new to treatment20.2% against 13.7% at week 72randomized trial, but not of switching
    Simulationmodelled from the diabetes trialsfurther loss predicted after a switch, even at 5 mga model
    Dulaglutide switch trialadults with type 2 diabetesmore weight loss after switching than after raising the old drugrandomized trial, a different starting drug
    Clinic series15 adults with type 2 diabetes6.6 kg in 3 months at 10 mgvery small, no comparison group

    The pieces point the same way, and none of them is a trial of Wegovy to Zepbound in people with obesity.

    Will the side effects start over?

    They may, because the Zepbound dose is stepped up from the bottom, and the labels of both drugs place most stomach side effects in the step-up period. The Zepbound label: "The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time."1 In the head-to-head trial the same was seen for both drugs: side effects "occurred primarily during dose escalation".5

    Side effects on each drugLabel tables
    Side effect

    People per 100 who reported the effect at any time in each drug's own trials. The two placebo rows show how differently the two sets of trials counted complaints, which is why the drug rows cannot simply be compared.

    People per 100Wegovy 2.4 mgIts placeboZepbound 5 mg10 mg15 mgIts placebo
    Nausea44162529288
    Diarrhea30161921238
    Vomiting246811132
    Constipation24111714115
    Stopped because of side effects6.83.24.86.36.73.4

    Wegovy label, Table 3, and Zepbound label, Table 1.

    The figures for Zepbound are lower than those for Wegovy, and so are the figures in Zepbound's placebo group, by about half. The two sets of trials counted complaints differently, so the table does not prove that Zepbound is easier on the stomach. The last row, the share who gave up treatment over side effects, is nearly the same for the two.

    Having tolerated Wegovy is no guarantee for Zepbound. The two drugs act on an overlapping set of receptors, not an identical one, and nothing in the labels says that getting used to one carries over to the other. The Japanese series offers a small reassurance: among its 15 switchers, "no gastrointestinal adverse events were reported during tirzepatide dose escalation or maintenance", and nobody stopped the drug.7 Fifteen people cannot settle the matter.

    This is the argument for the label's low start. A switcher who begins at 2.5 mg, with semaglutide still in the body, meets the new drug gently. A switcher who begins at a matched higher dose gets more effect and takes more risk of a rough first month. The article on the side effects timeline has the detail on when they come and go.

    When should the first Zepbound dose be?

    Neither label names a day. Both drugs are weekly, so the natural choice, and the one with no time off treatment, is the day the next Wegovy dose would have been due. On that day the semaglutide level is at its usual weekly low, about 62% of its peak in our model.

    Going earlier than a week would put a first dose of the new drug on top of a higher level of the old one. The labels' advice against using the two together is the nearest thing to a rule against that.

    Going later is a choice between two costs. Each week of waiting lowers the semaglutide further: 31% at two weeks, 16% at three, 8% at four. Less old drug may mean an easier first dose of the new one. It also means more weeks with little treatment, on top of the four weeks at Zepbound's starter dose.

    People on Wegovy tablets are in the same position on timing. The label says semaglutide stays in the circulation for about 5 to 7 weeks after the last 25 mg tablet as well, so the fade shown in the chart applies to them too.2 The label does not say on which day after the last tablet a weekly injection of another drug should begin.

    Once on Zepbound, the day of the week can be moved if it does not suit. The label allows a change as long as at least 3 days, 72 hours, pass between two doses.1

    What else changes with the switch?

    Four practical things differ between the two labels, and each can matter more than the dose.

    Birth control pills

    This is the change most easily missed. The Wegovy label has no instruction about contraceptive pills. The Zepbound label does: people who take the pill should switch to a non-oral method or add a barrier method "for 4 weeks after initiation" and "for 4 weeks after each dose escalation".1 Someone who moves from Wegovy to Zepbound and takes the pill goes from no rule to a rule on the day of the first injection. The article on Zepbound and birth control works out the backup weeks by date.

    Pregnancy plans

    The two drugs have different lead times. The UK regulator advises stopping semaglutide at least 2 months before trying to conceive and tirzepatide at least 1 month.3 In the first weeks after a switch both clocks are running, and the longer one, for the semaglutide still in the body, is the one that counts.

    What each drug is approved for

    The two labels do not cover the same conditions.

    Approved useWegovyZepbound
    Weight reduction in adultsyesyes
    Weight reduction from age 12yesno, adults only
    Lowering the risk of heart attack and stroke in adults with heart diseaseyesno
    A form of fatty liver disease with scarring (MASH)yesno
    Obstructive sleep apnea in adults with obesitynoyes

    Indications sections of the two labels, 2026 revisions.

    Someone who was put on Wegovy because of established heart disease is on it for a use that Zepbound's label does not have. For that person a switch for the sake of more weight loss is a different trade, and one to talk through with the cardiologist as well as the prescriber.

    Other medicines taken by mouth

    Both drugs slow the emptying of the stomach, and both labels carry a general caution about medicines swallowed as tablets. The Zepbound label is the more specific: it "has the potential to impact the absorption of concomitantly administered oral medications", and it asks for monitoring of medicines that depend on a precise level, with warfarin as its example.1 The effect is strongest after the first dose and at each increase, so the first months after a switch are the time to mention every tablet you take.

    The schedule

    Wegovy reaches its 2.4 mg dose in 16 weeks at the fastest pace. Zepbound takes 20 weeks to reach 15 mg, with stops available at 5 and 10 mg. A switcher restarts that clock: 4 weeks at 2.5 mg, then at least 4 weeks on each further step.

    Which day-to-day rules change?

    The two labels differ in several small rules that a person has learned on one drug and has to relearn on the other.12

    RuleWegovy injectionZepbound
    A missed dosetake it if the next dose is more than 2 days awaytake it within 4 days (96 hours), otherwise skip
    Two or more doses missed in a rowrestart the step-up at a lower dosethe label gives no rule
    Changing the injection dayat least 2 days between dosesat least 3 days (72 hours) between doses
    Single-dose pen out of the refrigeratorup to 28 days at 46 to 86°Fup to a total of 21 days at up to 86°F
    Strengths0.25, 0.5, 1, 1.7, 2.4 and 7.2 mg2.5, 5, 7.5, 10, 12.5 and 15 mg
    Rule for birth control pillsnonebackup for 4 weeks after starting and after each increase

    Wegovy and Zepbound labels, 2026 revisions.

    The missed-dose windows are the ones most likely to trip up a switcher. On Wegovy the question was how far away the next dose is. On Zepbound it is how long ago the missed one was. The article on missed doses has a checker for both, and the one on storage covers the pens out of the fridge.

    What about switching from Zepbound to Wegovy?

    The same absence of rules applies in the other direction, and the same logic. The Wegovy label starts everyone at 0.25 mg for 4 weeks and climbs through 0.5, 1 and 1.7 mg to reach 2.4 mg in week 17.2 Tirzepatide leaves the body a little faster than semaglutide: with a half-life of about 5 days, our model puts it at 17% of its usual peak two weeks after the last dose, 6% after three and under 1% after five.

    Days after the last Zepbound doseTirzepatide left, share of its usual peak
    744%
    1417%
    216%
    282.4%
    350.9%

    Our model with the Zepbound label's half-life of about 5 days.

    The handover is thinner in this direction. Tirzepatide is at 17% of its peak a week into the Wegovy step-up, where semaglutide would still be at 31%, and Wegovy's first dose, 0.25 mg, is a tenth of its usual 2.4 mg.

    The expected result is different. In the head-to-head trial the semaglutide group lost 13.7% against 20.2% on tirzepatide, so someone who moves from a full dose of Zepbound to Wegovy is moving to the drug with the smaller average effect, and through a 16-week climb to reach its usual dose. Wegovy now has a 7.2 mg dose, which produced an average loss of 18.8% in its trial, and the label allows it after at least 4 weeks on 2.4 mg.

    Reasons to go that way exist. Wegovy has the heart and liver indications, an approval from age 12, and a tablet form. No trial among the sources here measured what happens to weight after this switch.

    Is it the same for Ozempic to Mounjaro?

    The substances are the same: Ozempic is semaglutide and Mounjaro is tirzepatide, both approved for type 2 diabetes. The half-lives and the overlap in the body are therefore the same as in the calculator above. Most of the evidence on switching comes from this side: the simulation, the dulaglutide switch trial and the Japanese series were all in people with diabetes.

    One thing is more pressing with diabetes. The Zepbound label notes that the dose of insulin or a sulfonylurea may need to be reduced when tirzepatide is added, to lower the risk of low blood sugar.1 A switch in someone on those medicines is a matter for the diabetes team.

    How common is switching?

    Less common than the online discussion suggests. A study from a US academic medical centre followed 9,189 adults with obesity and without diabetes for a year after they started semaglutide or tirzepatide. Its authors report that prescriptions "to reinitiate or switch to another GLP-1 RA or first-generation AOM were rare".10

    The study sorted people by how many days of the year their prescriptions covered: under 32 days for 36.7%, 32 to 179 days for 27.0%, 180 to 335 days for 17.7%, and 336 days or more for 18.6%.

    The much larger movement was out of treatment. For 36.7% of the people, prescriptions covered less than 32 days. Only 18.6% had prescriptions covering at least 336 days of the year. For most people who struggle on one of these drugs, the path taken is stopping, not switching.

    What should I settle with my prescriber?

    1. The starting dose. The label says 2.5 mg. If a higher start is being considered, ask what it is based on.
    2. The date of the first dose. A week after the last Wegovy dose leaves no gap.
    3. The reason Wegovy was prescribed. If it was for heart disease or liver disease, ask what the switch means for that.
    4. Contraception. If you take the pill, the Zepbound rule starts with the first injection.
    5. What to do about side effects in the first month. Whom to call, and at what point to pause.
    6. When to review. A date to look at weight and tolerance and decide on the next step up.

    What can this page not tell you?

    There is no trial of this switch in obesity. The comparison of the drugs is solid. What happens to one person who changes from one to the other is inferred.

    The level chart is a model. It uses the half-lives in the labels and a simple absorption curve. It shows how much drug is in the body. It cannot show how the two drugs' effects add up while both are present.

    Results from different trials are not a conversion table. Matching Wegovy 2.4 mg with Zepbound 5 mg rests on averages from separate studies.

    The makers funded most of it. SURMOUNT-5 was funded by Eli Lilly, which sells Zepbound. The labels are written by the companies and approved by the FDA.

    Short answers to common questions

    What dose of Zepbound do I start on after Wegovy 2.4 mg?

    The label gives 2.5 mg once a week for 4 weeks for everyone, with no separate rule for switchers. A 2026 expert review proposes matched higher starting doses as an option, pending trials. Starting above 2.5 mg is outside the label and is the prescriber's decision.

    Do I need a washout period?

    The labels do not ask for one. Semaglutide stays in the body for 5 to 7 weeks either way. With no gap, the first Zepbound dose goes in a week after the last Wegovy dose.

    Can I take Wegovy and Zepbound together?

    No. Both labels say that use with another GLP-1 receptor agonist is not recommended.

    Is Wegovy 2.4 mg equal to Zepbound 5 mg?

    Their average results in separate trials were about the same, 14.9% and 15.0%. That is a rough match, not an official equivalence.

    Will I gain weight during the switch?

    With no gap, the semaglutide still in the body covers part of the four weeks on the starter dose. With a gap of several weeks, there is a stretch with little drug, and the stopping trials show weight tends to return in such stretches.

    Will I lose more on Zepbound?

    In the head-to-head trial the average loss was 20.2% on tirzepatide and 13.7% on semaglutide. That trial was in people new to treatment. No trial has measured the gain from switching.

    Will I get nausea again?

    Possibly. Most stomach side effects on Zepbound occur while the dose is being raised, and a switch means going through that step-up.

    Does my birth control still work?

    If it is a pill, the Zepbound label asks for a backup or a non-oral method for 4 weeks after starting and after each dose increase. Wegovy has no such rule.

    Can I switch back?

    Yes, with the Wegovy step-up from 0.25 mg. In the head-to-head trial the average loss on semaglutide was smaller.

    Do I restart at 2.5 mg even after Wegovy 7.2 mg?

    By the label, yes. Its starting dose does not depend on what was taken before. On the published averages, Wegovy 7.2 mg (18.8%) sits close to Zepbound 10 mg (19.5%), so the step down to 2.5 mg is larger for someone coming from the high dose.

    How long until Zepbound is at full strength after the switch?

    The level on 5 mg settles about 8 weeks after the first Zepbound dose. Reaching 15 mg takes 20 weeks at the fastest pace the label allows, and the level settles about 4 weeks after that.

    Is it worth switching because of side effects on Wegovy?

    The trials cannot answer that for one person. The label tables show lower figures for Zepbound, but its placebo group also reported less, so the tables are not comparable. The share who stopped over side effects was about the same on both drugs.

    How the calculator works

    The calculator runs two copies of our level model. For semaglutide it assumes a long course of weekly doses ending on the date you enter, and follows the level down with the Wegovy label's half-life of about 1 week. For tirzepatide it adds the label's doses, 2.5 mg weekly for four weeks and 5 mg after that, starting on the day you choose, with a half-life of about 5 days. Each line is drawn as a share of that drug's own usual level, so the two lines show timing and are not a comparison of strength. "Wegovy gone by" is the first day on which the semaglutide level is under 5% of its usual peak.

    The loss chart shows the average results in the clinical studies sections of the two labels and in the head-to-head trial. The side effect chart shows the main table of each label.

    Sources

    1. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2.1, 2.3, 6.1, 7.2, 8.3, 12.3 and 14.1. accessdata.fda.gov
    2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1, 2.2, 2.5, 6.1, 12.3 and 14. accessdata.fda.gov
    3. Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes: what you need to know. Guidance, updated 5 February 2026. gov.uk
    4. Schwartzberg E, Berman E, Shani S, et al. Switching between semaglutide and tirzepatide in obesity management: an expert-consensus framework for approximate clinical efficacy-matched switching doses. Expert Opin Pharmacother 2026. doi:10.1080/14656566.2026.2756017
    5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. doi:10.1056/NEJMoa2416394
    6. Urva S, Levine JA, Schneck K, Tang CC. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide. Curr Med Res Opin 2024;40:567-574. doi:10.1080/03007995.2024.2322072
    7. Kurinami N, Takada M, Sugiyama S, et al. Early dose escalation of tirzepatide after switching from semaglutide in type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2025;40:1012-1015. doi:10.3803/enm.2025.2420
    8. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414-1425. doi:10.1001/jama.2021.3224
    9. Violante-Ortiz R, Rose L, Sharma P, et al. Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. BMJ Open Diabetes Res Care 2026;14:e005711. doi:10.1136/bmjdrc-2025-005711
    10. Ali D, Kudaya D, Ngige A, Chao AM. Patterns of prescription discontinuation, reinitiation, and switching of subcutaneous semaglutide and tirzepatide in adults with obesity. Diabetes Obes Cardiometab CARE 2026;1:71-75. doi:10.2337/doc25-0026

    Related analyses

    Log both drugs in the app and it keeps one timeline across the switch.

    Open Dose Insider